Irofulven: resurgence for alkylating therapy in cancer?
Dent
Paul
P
Department of Radiation Oncology, 401 College Street, Box 980058, Virginia Commonwealth University, Richmond, Virginia 23298, USA. pdent@hsc.vcu.edu
Grant
Steven
S
D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D016193:G1 Phase / Q000187:drug effects*; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D008938:Mitosis / Q000187:drug effects*; D009369:Neoplasms / Q000188:drug therapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D016196:S Phase / Q000187:drug effects*; D012717:Sesquiterpenes / Q000494:pharmacology*
D018906:Antineoplastic Agents, Alkylating; D019253:Proto-Oncogene Proteins c-bcl-2; D012717:Sesquiterpenes; C102714:irofulven